Timber Creek Capital Management LLC held its position in shares of Allergan PLC. (NYSE:AGN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,752 shares of the company’s stock at the close of the second quarter. Allergan PLC. accounts for approximately 2.8% of Timber Creek Capital Management LLC’s investment portfolio, making the stock its 14th biggest position. Timber Creek Capital Management LLC’s holdings in Allergan PLC. were worth $3,763,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in the company. Global Endowment Management LP grew its stake in shares of Allergan PLC. by 4.6% in the second quarter. Global Endowment Management LP now owns 13,640 shares of the company’s stock worth $3,316,000 after purchasing an additional 600 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Allergan PLC. by 3.9% in the second quarter. Dimensional Fund Advisors LP now owns 1,668,088 shares of the company’s stock worth $405,510,000 after purchasing an additional 63,173 shares in the last quarter. Massey Quick & Co. LLC grew its stake in shares of Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after purchasing an additional 385 shares in the last quarter. Ropes Wealth Advisors LLC grew its stake in shares of Allergan PLC. by 5.2% in the second quarter. Ropes Wealth Advisors LLC now owns 605 shares of the company’s stock worth $147,000 after purchasing an additional 30 shares in the last quarter. Finally, Simonbaker & Partners LLC bought a new position in shares of Allergan PLC. in the second quarter worth $242,000. 82.03% of the stock is owned by institutional investors.

Several research firms have recently issued reports on AGN. UBS AG reissued an “outperform” rating and issued a $275.00 price target on shares of Allergan PLC. in a research note on Wednesday, August 9th. BidaskClub cut Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Barclays PLC reissued an “equal weight” rating on shares of Allergan PLC. in a research note on Monday, October 2nd. Wells Fargo & Company reissued an “outperform” rating and issued a $280.00 price target (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Finally, Argus reissued a “buy” rating and issued a $280.00 price target on shares of Allergan PLC. in a research note on Monday, August 14th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $271.64.

Allergan PLC. (AGN) opened at 206.75 on Friday. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The company’s 50-day moving average price is $218.50 and its 200 day moving average price is $233.15. The company has a market cap of $69.12 billion, a PE ratio of 6.30 and a beta of 1.15.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.35 earnings per share. On average, analysts anticipate that Allergan PLC. will post $16.21 EPS for the current year.

Allergan PLC. announced that its Board of Directors has approved a share repurchase program on Monday, September 25th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 2.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

The company also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were given a dividend of $0.70 per share. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.35%. Allergan PLC.’s payout ratio is currently 9.95%.

TRADEMARK VIOLATION WARNING: “Timber Creek Capital Management LLC Has $3,763,000 Stake in Allergan PLC. (AGN)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/timber-creek-capital-management-llc-has-3763000-stake-in-allergan-plc-agn/1617186.html.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.